Rusty Konkol wanted to hug everyone he saw during his tour of Iovance Biotherapeutics’ Navy Yard manufacturing facility. The ...

April 7, 2026) - BioOra Limited ("BioOra"), a commercial-stage cell therapy company advancing CAR-T therapies for cancer patients, and Octane Biotech Inc., an Octane Medical Group Company ("Octane"), ...

In cell therapy applications, commonly employed cell purification platforms for large-scale isolation of immune or stem cells separate cells based on a single cell surface antigen. Enrichment based on ...

Johnson & Johnson bets $1B on a Pennsylvania cell therapy plant as earnings momentum, pipeline deals, and MedTech approvals ...

As cell and gene therapy developers face rising pressure to produce therapies faster and at lower cost, the industry is ...

Thermo Fisher Scientific Inc., the world leader in serving science, today announced the global launch of the Gibco (TM) CTS (TM) Compleo (TM) Fill and Finish System, an automated, functionally closed ...

At its Navy Yard manufacturing facility, Iovance Biotherapeutics is transforming patients’ immune cells into lifesaving ...

Emerging pathways can help cell and gene therapies become commercially viable for intractable diseases, even with uneven scalability and consistency.

Cellares has raised a $257 million Series D financing, bringing its total funding to $612 million. The latest comes as the cell therapy manufacturing company accelerates plans to industrialize ...

Wugen, Inc., a clinical-stage biotechnology company developing allogeneic, off-the-shelf cell therapies for the treatment of ...

Personalized cell therapies have emerged as powerful treatments for cancers and other diseases but producing them remains a complex engineering challenge. Unlike conventional drugs, each cell therapy ...

The FDA has delayed its target decision date for Orca Bio’s blood cancer cell therapy candidate Orca-T by three months to ...